United Therapeutics (United Therapeutics) EPS (Basic) : $21.06 (TTM As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

What is United Therapeutics EPS (Basic)?

United Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $4.62. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $21.06.

United Therapeutics's EPS (Diluted) for the three months ended in Dec. 2023 was $4.36. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $19.84.

United Therapeutics's EPS without NRI for the three months ended in Dec. 2023 was $4.36. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was 19.84.

During the past 12 months, United Therapeutics's average EPS without NRIGrowth Rate was 31.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was 19.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, United Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 155.30% per year. The lowest was -39.40% per year. And the median was 19.15% per year.

United Therapeutics EPS (Basic) Historical Data

The historical data trend for United Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics EPS (Basic) Chart

United Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-2.39

11.65

10.60

15.98

21.04

United Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Basic)	Get a 7-Day Free Trial															2.88	5.20	5.53	5.71	4.62

United Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

United Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(984.8	-	0)	/	46.800
	=	21.04

United Therapeutics's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(217.1	-	0)	/	47.100
	=	4.61

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $21.06

United Therapeutics (NAS:UTHR) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

United Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of United Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

United Therapeutics (United Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (NAS:UTHR) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

UTH:Germany

Address

1040 Spring Street, Silver Spring, MD, USA, 20910

Website

https://www.unither.com

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

Executives

Paul A Mahon	officer: EVP & General Counsel
Nilda Mesa	director	C/O UNITED THERAPEUTICS CORPORATION, 1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Causey	director
Martine A Rothblatt	director, officer: Chief Executive Officer
Louis W Sullivan	director
Judy D. Olian	director	2000 AVENUE OF THE STARS 12TH FL, LOS ANGELES CA 90067
Michael Benkowitz	officer: President and COO	C/O UNITED THERAPEUTICS CORP, 1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Patusky	director
Raymond Dwek	director
Linda Maxwell	director	1040 SPRING STREET, SILVER SPRING NC 27709
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105
Katherine J Klein	director	STEINBERG HALL-DIETRICH HALL, 3620 LOCUST WALK, PHILADELPHIA PA 19104
Richard Giltner	director	C/O UNITED THERAPEUTICS CORPORTION, 1735 CONNECTICUT AVE. NW, WASHINGTON DC 20009
Roger Jeffs	director, officer: President and COO
David Zaccardelli	officer: EVP & Chief Operating Officer	300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069